DZ Bank reaffirmed their neutral rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a report issued on Wednesday morning.

Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a strong sell rating to a hold rating in a research note on Tuesday, July 3rd. Royal Bank of Canada restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday. Bank of America assumed coverage on Fresenius Medical Care AG & Co. in a research note on Monday, July 9th. They issued a buy rating for the company. HSBC upgraded Fresenius Medical Care AG & Co. from a hold rating to a buy rating in a research note on Tuesday, August 28th. Finally, Credit Suisse Group downgraded Fresenius Medical Care AG & Co. from an outperform rating to a neutral rating in a research note on Thursday, July 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $60.00.

NYSE:FMS opened at $40.44 on Wednesday. The stock has a market capitalization of $24.46 billion, a P/E ratio of 18.30, a PEG ratio of 1.89 and a beta of 0.80. Fresenius Medical Care AG & Co. has a one year low of $39.74 and a one year high of $57.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.37 and a quick ratio of 1.11.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 31st. The company reported $0.54 EPS for the quarter, missing the Zacks’ consensus estimate of $0.60 by ($0.06). The firm had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.28 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.78% and a net margin of 11.65%. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter last year, the business posted $0.89 earnings per share. On average, analysts predict that Fresenius Medical Care AG & Co. will post 2.46 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. Northern Trust Corp boosted its stake in Fresenius Medical Care AG & Co. by 2.5% in the second quarter. Northern Trust Corp now owns 838,500 shares of the company’s stock valued at $42,219,000 after acquiring an additional 20,391 shares during the period. Royal Bank of Canada boosted its stake in Fresenius Medical Care AG & Co. by 5.8% in the first quarter. Royal Bank of Canada now owns 590,198 shares of the company’s stock valued at $30,148,000 after acquiring an additional 32,612 shares during the period. Aperio Group LLC boosted its stake in Fresenius Medical Care AG & Co. by 6.5% in the second quarter. Aperio Group LLC now owns 254,964 shares of the company’s stock valued at $12,837,000 after acquiring an additional 15,616 shares during the period. Millennium Management LLC boosted its stake in Fresenius Medical Care AG & Co. by 80.8% in the first quarter. Millennium Management LLC now owns 146,984 shares of the company’s stock valued at $7,508,000 after acquiring an additional 65,707 shares during the period. Finally, Ferguson Wellman Capital Management Inc. acquired a new position in Fresenius Medical Care AG & Co. in the second quarter valued at approximately $7,359,000. Institutional investors own 2.46% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Further Reading: How to interpret a stock’s beta number

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.